Dissolving microarray patches loaded with a rotigotine nanosuspension: A potential alternative to Neupro® patch

Area of Science:

• Pharmaceutical Sciences
• Biomaterials Engineering
• Drug Delivery Systems

Background:

• Parkinson's disease (PD) affects millions globally, posing a significant therapeutic challenge.
• Current transdermal rotigotine (RTG) patches (Neupro®) can cause skin irritation and require daily application.
• There is a need for improved transdermal delivery systems for PD management.

Purpose of the Study:

• To develop and evaluate a novel dissolving microarray patch (MAP) for transdermal delivery of rotigotine (RTG) using a nanosuspension (NS) formulation.
• To compare the efficacy of the RTG-NS MAP with the conventional Neupro® patch.
• To assess the potential of RTG-NS MAPs as an improved alternative for Parkinson's disease treatment.

Main Methods:

• Formulation of RTG-NS using miniaturized media milling, characterized by particle size, PDI, and zeta potential.
• In vitro dissolution studies comparing RTG-NS with coarse RTG powder.
• Ex vivo transdermal delivery studies using Franz cells with neonatal porcine skin.
• In vivo pharmacokinetic evaluation in comparison to Neupro®.

Main Results:

• RTG-NS exhibited enhanced dissolution compared to coarse RTG powder.
• RTG-NS MAPs demonstrated significantly higher drug delivery per unit area than Neupro® in ex vivo studies.
• In vivo studies showed comparable drug levels with RTG-NS MAPs to Neupro®, despite smaller patch size, indicating higher efficiency.

Conclusions:

• The developed RTG-NS MAP provides an efficient transdermal drug delivery system for rotigotine.
• Dissolving MAP technology offers potential advantages over conventional transdermal patches for Parkinson's disease treatment.
• This approach may lead to better patient compliance and reduced side effects compared to existing treatments.